Abstract
Background: Pazopanib became a treatment option for metastastic soft tissue sarcoma (STS), after failure of standard chemotherapy, following the PALETTE study (2012), which showed improvement in progression-free survival (PFS). In 2015 retrospective analysis of 13 patients with metastatic STS treated with pazopanib was collected; we have now reviewed a further 2 years worth of data throughout the four Sarcoma centres in Scotland. Methods: Retrospective analysis of 31 patients with metastatic STS treated with pazopanib was performed. The primary outcomes were PFS; overall survival (OS); toxicity data and tolerability of therapy. Results: Retrospective analysis identified 31 patients in total treated with pazopanib (median age 53.7years). All patients had advanced non-adipocyte, angiogenesis inhibitor- naïve STS prior to commencing therapy. Median PFS was 3.9 months (95% CI 2.2-5.6 months) and median OS 7.2 months (95% CI 4.5-9.6 months). 7 patients (23%) suffered grade 3-4 toxicity: diarrhoea; skin/hair pigmentation; LFT derangement; ‘unknown’. The most common grade 1-2 adverse events were skin/hair pigmentation (48%), diarrhoea (42%) and hypertension (42%). Conclusion: This retrospective analysis shows that while PFS is comparable to the influential PALETTE trial, OS is worse (7.2 months vs. 12.5months). We believe our data reveals more ‘real-life’ outcomes and experience, and continues to highlight that Pazopanib is a well-tolerated treatment option in patients with metastatic STS that provides an improvement in PFS. Further review of a subset of the patients to compare RECIST (Response Evaluation Criteria in Solid Tumours) response with clinically defined benefit and time to best RECIST response is ongoing.
Original language | English |
---|---|
Number of pages | 1 |
Publication status | Published - 26 Feb 2018 |
Event | British Sarcoma Group Annual Conference - The Repertory Theatre, Birmingham, United Kingdom Duration: 27 Feb 2018 → 28 Feb 2018 |
Conference
Conference | British Sarcoma Group Annual Conference |
---|---|
Country/Territory | United Kingdom |
City | Birmingham |
Period | 27/02/18 → 28/02/18 |
Keywords
- soft tissue sarcoma
- chemotherapy
- pazopanib